glp 1 drugs compounded FDA says that the GLP-1 shortage is over GLP-1 Compounding: When Innovation May
Description
It should be noted that this study was funded by Novo Nordisk, the pharmaceutical company that produces semaglutide
In contrast, gastrointestinal side effects were reported in 10 of the 11 studies and were consistently more common in the intervention groups
They might suggest referral to an endocrinologist for comprehensive metabolic assessment, or to a specialist weight management service if obesity is a significant concern
However, because phentermine is a stimulant, it may raise blood sugar through stress hormones
Conclusion The intersection of GLP-1 weight loss medications and life insurance underwriting is creating new challenges for agents and clients alike
Industry press noted the deal values escalating and legal skirmishes ( [44] ) ( [50] )
